I. Introduction:
Urolithin A (UA) is the most clinically validated mitochondrial health ingredient for longevity supplements. As a cGMP OEM/ODM manufacturer, we develop science-backed Urolithin A stack formulas that brands launch into the $9.2 billion global longevity supplements market.
This page is for brand owners, product developers, and procurement teams evaluating Urolithin A formula options for their next product launch.
Best Urolithin A Supplement Stack Combinations (2026)
| Formula Tier | Best For | Key Ingredients | Dose Range | MOQ |
|---|---|---|---|---|
| Entry Formula | Mass market, daily energy | Urolithin A + CoQ10 + B3 | UA 250–500mg | 5,000 units |
| Growth Formula | Premium longevity, biohackers | Urolithin A + NMN + PQQ + CoQ10 | UA 500mg | 5,000 units |
| Clinical Stack | Ultra-premium, autophagy | UA + NMN + Spermidine + CoQ10 + Resveratrol | UA 500–1000mg | 5,000 units |
II. Clinical Evidence Hierarchy
Tier 1: Human Clinical Trials (Primary Evidence)
| Trial | NCT Number | Dose | Key Finding | Population |
|---|---|---|---|---|
| ATLAS | NCT03464500 | 500mg/day | ↑Leg muscle strength ~12%; ↑6-min walk distance | Overweight middle-aged (40–65) |
| ENERGIZE | NCT03283462 | 1000mg/day | ↑Muscle endurance; ↓CRP, ↓acylcarnitines, ↓ceramides | Older adults (65–90) |
| MitolMMUNE | NCT05735886 | 1000mg/day | Immune metabolic reprogramming; ↑naive CD8+ T cells | Middle-aged (45–70) |
| Bioavailability | NCT06853197 | Various | 7 formulation variants tested for absorption optimization | Healthy adults |
Source: Singh A, et al. Cell Reports Medicine (2022); Ryu D, et al. JAMA Network Open (2022); Nature Aging (2025).
Tier 2: Regulatory Safety Validation
- FDA GRAS GRN 000791 — Urolithin A approved up to 1,000mg/serving for dietary supplements
- 28-day and 90-day rodent toxicity studies completed
- Multiple Phase 1/2 human safety trials with no serious adverse events
Tier 3: Market Demand Validation
- Global longevity supplements market: $9.2B (2025) → $16.7B (2033) at 7.7% CAGR
- U.S. longevity market: $10.13B by 2033 at 8.91% CAGR
- NMN market: $0.73B (2026) → $3.89B (2035) at 20.2% CAGR
- Spermidine market: $0.3B (2025) → $0.7B (2034) at 12.5% CAGR
- PQQ market: $128.4M (2024) → $305.9M (2033) at 10.3% CAGR
III. Which Formula Should You Choose?
Entry Formula: Urolithin A + CoQ10
Best for: First-time longevity brands, mass market energy positioning, Amazon/DTC under $69/month
Mechanism Snapshot:
| Pathway | Ingredients | Function |
|---|---|---|
| Mitophagy | Urolithin A (250–500mg) | Clears damaged mitochondria |
| Energy Output | CoQ10 (100–200mg) | Optimizes ATP production |
| NAD+ Support | Niacinamide (50–100mg) | Salvage pathway support |
Why it sells: Lowest barrier to entry. Targets the 35–55 demographic seeking daily energy. CoQ10 is oxidation-sensitive—requires nitrogen-flushed encapsulation.
Growth Formula: Urolithin A + NMN + PQQ + CoQ10
Best for: Premium longevity brands, biohacker positioning, $89–$149/month DTC
Mechanism Snapshot:
| Pathway | Ingredients | Function |
|---|---|---|
| Mitophagy | Urolithin A (500 mg) | Removes dysfunctional mitochondria |
| Biogenesis | NMN (250–500mg) + PQQ (10–20mg) | Creates new mitochondria |
| Energy Output | CoQ10 (100–200mg) | Maximizes electron transport |
Why it sells: The “sweet spot” formula—fastest-growing configuration at +35% YoY. Combines the three pillars of mitochondrial health. NMN is hygroscopic; requires <40% RH manufacturing. PQQ is heat-sensitive; blending must stay below 35°C.
Clinical Stack: Urolithin A + NMN + Spermidine + CoQ10 + Resveratrol
Best for: Ultra-premium positioning, longevity clinics, $179–$299/month practitioner channel
Mechanism Snapshot:
| Pathway | Ingredients | Function |
|---|---|---|
| Mitophagy | Urolithin A (500–1000mg) | Deep mitochondrial clearance |
| Autophagy | Spermidine (2–5mg) | Broad cellular recycling |
| Biogenesis | NMN (500–600mg) | NAD+ & new mitochondria |
| Energy Output | CoQ10 (200–300mg) | Maximum ATP |
| Longevity Signaling | Resveratrol (100–250mg) | SIRT1 activation |
Why it sells: Most comprehensive stack on the market. 1000mg Urolithin A demonstrated immune metabolic reprogramming in Nature Aging (NCT05735886). Spermidine market growing at 12.5% CAGR; North America commands 38.2% share. Requires bilayer tablets or dual-capsule systems to isolate incompatible actives.
IV. OEM Quick RFQ Snapshot
| Specifications | Details |
|---|---|
| MOQ | 5,000 units (hard capsules/tablets); 10,000 units (softgels / liposomal) |
| Sample Lead Time | 7–10 days for prototype; 4–6 weeks for pilot batch |
| Custom Formula | Yes — full stack design from concept to COA |
| Private Label | Yes — ready-to-launch formulas available |
| Regulatory Support | FDA notification, structure/function claims review, EU/UK/APAC compliance |
| Standard Lead Time | 6–8 weeks (commercial); 8–10 weeks (liposomal) |
| Certifications | cGMP, FDA-registered, NSF, ISO 9001:2015 |
V. Dosage & Delivery Form Guide
Urolithin A Clinical Dosing
| Dose | Outcome | Trial |
|---|---|---|
| 250mg | Mitochondrial gene expression; safe bioavailability | Phase 1 (NCT02655393) |
| 500mg | ↑Muscle strength ~12%; ↑6-min walk | ATLAS (NCT03464500) |
| 1000mg | ↑Endurance; ↓inflammation markers; immune reprogramming | ENERGIZE (NCT03283462); MitolMMUNE (NCT05735886) |
Co-Ingredient Dosing
| Ingredient | Standard Dose | Key Consideration |
|---|---|---|
| NMN | 250–600mg | Hygroscopic; <40% RH manufacturing required |
| CoQ10 (Ubiquinol) | 100–300mg | 2–4x more bioavailable than ubiquinone in 40+ adults |
| PQQ | 10–20mg | Heat-sensitive; blending <35°C |
| Spermidine | 2–5mg | Moisture-sensitive; specialized encapsulation |
| Resveratrol | 100–250mg | Photodegradable; amber packaging + nitrogen flush |
Delivery Form Selection
| Form | Cost | Bioavailability | Best For |
|---|---|---|---|
| Hard Capsule (Gelatin/HPMC) | ★★★★★ | Standard | Mass market, cost efficiency |
| Vegan Capsule (Pullulan) | ★★★★☆ | Standard | Clean-label, EU market |
| Softgel | ★★★☆☆ | Enhanced (lipids) | CoQ10, fat-soluble stacks |
| Liposomal | ★★☆☆☆ | +2–5x | Premium NMN, resveratrol |
| Enteric-Coated | ★★★☆☆ | Gastric protection | Acid-sensitive actives |
VI. Stability & Formulation Engineering
Challenges We Solve
| Challenge | Problem | Our Solution |
|---|---|---|
| Oxidation | CoQ10/resveratrol degrade in oxygen | Nitrogen-flushed blending (<2% O₂); antioxidant excipients; oxygen-barrier packaging |
| Hygroscopicity | NMN clumps, loses potency | RH <35% environment; immediate encapsulation; silica gel canisters |
| Interaction | Multi-actives have incompatible properties | Pre-blend segregation (lipophilic vs. hydrophilic phases); DSC/FTIR compatibility screening |
| Flowability | >50% active content = poor flow | Gravimetric feeders (±1%); silicon dioxide; fluid-bed granulation |
Evidence: Cocrystal ubiquinol achieved 2.2x higher Cmax and 2.0x higher AUC vs. standard ubiquinone under stressed conditions (40°C, 75% RH).
VII. Manufacturing Capability Proof
Facility & Certifications
- FDA-registered dietary supplement facility
- cGMP compliant (21 CFR Part 111)
- NSF Certified for Sport and standard manufacturing
- ISO 9001:2015 quality management
- Allergen-free dedicated lines
Equipment & Capacity
| System | Specifications |
|---|---|
| Blending | 200L–2,000L V-blenders and ribbon blenders |
| Encapsulation | 6 high-speed lines (up to 300,000 capsules/hour) |
| Tableting | 10-station to 45-station rotary presses |
| Coating | Film, enteric, and sugar coating |
| Packaging | Automated bottling, blister, sachet, stick pack |
| QC Lab | In-house HPLC, GC-MS, ICP-MS, microbiology |
Quality Control Per Batch
- Identity: FTIR + HPLC for all actives
- Potency: HPLC assay vs. USP/EP standards
- Purity: Heavy metals (Pb, Cd, As, Hg), residual solvents, pesticides
- Microbial: TAMC, yeast/mold, E. coli, Salmonella, S. aureus
- Stability: Real-time + accelerated per ICH Q1A(R2)
[Manufacturing Proof Gallery] (Insert: Cleanroom photo / Capsule production line / HPLC testing lab / Stability chamber / Encapsulation process)
VIII. 2026+ Formulation Trends
| Trend | What It Means for Your Brand |
|---|---|
| Mitophagy + NAD+ Dual Pathway | Lead with Urolithin A (mitophagy) + NMN (biogenesis) as the core story |
| Autophagy Stacking | Spermidine + Urolithin A is the next premium combination; market growing at 12.5% CAGR |
| Reduced-Pill Compliance | Consumer drop-off beyond 3 capsules/day; use high-density granulation to compress stacks |
| Clinically Transparent | Publish exact doses, COAs, and trial references—”Blueprint-style” formulations win trust |
| Advanced Delivery | Liposomal NMN and nano-emulsified CoQ10 command $150–$250+ price points |
Global anti-aging supplements market projected to reach $9.06B by 2033.
Frequently Asked Questions (FAQ)
Q1: What is the best Urolithin A formula?
For most brands launching in 2026, the Growth Formula (Urolithin A 500mg + NMN 250mg + PQQ 10mg + CoQ10 100mg) offers the best balance of clinical credibility, consumer demand, and premium pricing. It targets the fastest-growing segment at +35% YoY.
Q2: Can Urolithin A be combined with NMN?
Yes. They target complementary pathways with no known negative interactions. Urolithin A holds FDA GRAS status (GRN 000791) at up to 1,000mg/day. NMN has been safely studied at doses up to 1,200mg/day. Note: NMN faces FDA regulatory review as a potential drug—consult legal counsel on marketing claims.
Q3: What is the recommended dosage for longevity formulas?
- Urolithin A: 500mg/day (muscle strength); 1,000mg/day (immune metabolic reprogramming)
- NMN: 250–500mg/day
- CoQ10: 100–200mg/day (ubiquinol for 40+)
- PQQ: 10–20mg/day
- Spermidine: 2–5mg/day
Q4: What delivery form is best?
Hard capsules are most cost-efficient for Urolithin A. For stacks with CoQ10 or resveratrol, consider softgels or liposomal delivery. For NMN, use enteric-coated or acid-resistant capsules to protect from gastric degradation.
Q5: Do you provide OEM Urolithin A formula development?
Yes. End-to-end OEM/ODM including custom formula design, regulatory compliance (FDA/EU/APAC), cGMP manufacturing, stability testing, and packaging. MOQ: 5,000 units.
Q6: How do you ensure stability in multi-active formulas?
Multi-layer approach: DSC/FTIR compatibility screening → nitrogen-flushed blending → excipient engineering → oxygen/moisture-barrier packaging → real-time stability monitoring per ICH guidelines.
Q7: What certifications do you hold?
FDA-registered, cGMP (21 CFR Part 111), NSF Certified for Sport, ISO 9001:2015. Organic, Kosher, and Halal available upon request.
Q8: What is the lead time?
- Prototype: 2–3 weeks
- Pilot batch: 4–6 weeks
- Commercial: 6–8 weeks (standard); 8–10 weeks (liposomal)
- Total concept-to-shelf: 12–16 weeks
Ready to Launch Your Urolithin A Formula?
Get Your Custom Formula Quote
Tell us your target market, price point, and channel. Our formulation team will design your Urolithin A stack with full regulatory support and a cGMP manufacturing guarantee.
Or contact us directly:
- Email: donna.ks@kingsci.com
- Phone: +86 15319401177
- Response time: <24 hours
References & Data Sources
- Singh A, et al. (2022). “Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health.” Cell Reports Medicine. NCT03464500. https://pubmed.ncbi.nlm.nih.gov/35584623/
- Ryu D, et al. (2022). “Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults.” JAMA Network Open. NCT03283462. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788244
- Urolithin A immune metabolic reprogramming (2025). Nature Aging. NCT05735886. https://www.nature.com/articles/s43587-025-00996-x
- FDA GRAS Notice GRN 000791 — Urolithin A. https://www.fda.gov/media/120300/download
- FDA GRAS Notices Database. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/?set=GRASNotices&id=791
- Elam R, et al. (2024). “Randomized Crossover Clinical Trial of Nicotinamide Riboside and CoQ10.” NCT03579693. https://pmc.ncbi.nlm.nih.gov/articles/PMC11370499/
- Urolithin A bioavailability formulations (2025). CenterWatch NCT06853197. https://www.centerwatch.com/clinical-trials/listings/NCT06853197/bioavailability-of-seven-mitopure-formulations
- Global Dietary Supplements Market (2025). Precedence Research. https://www.globenewswire.com/news-release/2025/12/17/3207029/
- Healthy Aging Supplement Market (2026). The Business Research Company. https://www.thebusinessresearchcompany.com/report/healthy-aging-supplement-global-market-report
- U.S. Longevity & General Wellness Supplements (2026). Grand View Research. https://www.grandviewresearch.com/industry-analysis/us-longevity-general-wellness-supplements-market-report
- Global Longevity Supplements Market (2026). Metastat Insight. https://metastatinsight.com/report/longevity-supplements-market
- Beta-NMN Market (2026). Business Research Insights. https://www.businessresearchinsights.com/market-reports/beta-nicotinamide-mononucleotide-nmn-market-104605
- Spermidine Supplements Market (2026). MarketIntelo. https://marketintelo.com/report/spermidine-supplements-market
- PQQ Supplements Market (2025). DataIntelo. https://dataintelo.com/report/pyrroloquinoline-quinone-supplements-market
- Cocrystal Ubiquinol Bioavailability (2024). Pharmaceutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC12965043/
- Liposomal Vitamin C Bioavailability (2026). Natural Resources for Human Health. https://www.nrfhh.com/pdf-211489-134738
- Alzheimer’s Drug Discovery Foundation — Urolithin A Evidence Summary (2024). https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Urolithin_A_UPDATE_%28supplement%29.pdf
- Longevity Market Size Analysis (2026). New Market Pitch. https://newmarketpitch.com/blogs/news/longevity-market-size
- Anti-Aging Supplements Market (2026). Grand View Research. https://www.grandviewresearch.com/industry-analysis/anti-aging-supplements-market-report
- Urolithin A Clinical Trials Registry. ClinicalTrials.gov NCT06556706. https://clinicaltrials.gov/study/NCT06556706
Last Updated: June 2026 | All clinical and market data verified against primary sources. This page is intended for B2B procurement and product development professionals. Structure/function claims have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
